SMARCA1 and cancer: In cancers driven by mutations in the SWI/SNF chromatin remodelling complex, such as rhabdoid sarcoma and small cell carcinoma of the ovary, EZH2 inhibition exploits a specific dependency on PRC2 function,22, 23, 24 vide infra.